Marshall Wace LLP Purchases 1,191,774 Shares of Immunome, Inc. (NASDAQ:IMNM)

Marshall Wace LLP raised its position in Immunome, Inc. (NASDAQ:IMNM) by 228.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,713,325 shares of the company’s stock after buying an additional 1,191,774 shares during the quarter. Marshall Wace LLP’s holdings in Immunome were worth $20,731,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in IMNM. Arizona State Retirement System increased its stake in Immunome by 9.2% in the second quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock valued at $131,000 after acquiring an additional 918 shares during the last quarter. Clear Creek Financial Management LLC increased its stake in shares of Immunome by 18.2% in the 2nd quarter. Clear Creek Financial Management LLC now owns 26,188 shares of the company’s stock valued at $317,000 after purchasing an additional 4,035 shares during the last quarter. EntryPoint Capital LLC raised its holdings in shares of Immunome by 21,864.0% during the 1st quarter. EntryPoint Capital LLC now owns 5,491 shares of the company’s stock worth $136,000 after buying an additional 5,466 shares in the last quarter. Quest Partners LLC bought a new stake in shares of Immunome during the 2nd quarter worth $81,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Immunome in the second quarter valued at about $97,000. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

IMNM has been the subject of a number of research reports. Wedbush reissued an “outperform” rating and issued a $33.00 target price on shares of Immunome in a report on Tuesday, August 13th. Piper Sandler cut their target price on shares of Immunome from $27.00 to $23.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 13th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $29.00.

Immunome Price Performance

NASDAQ:IMNM opened at $14.34 on Friday. Immunome, Inc. has a one year low of $6.93 and a one year high of $30.96. The company has a market cap of $861.12 million, a PE ratio of -1.90 and a beta of 1.77. The firm’s 50 day simple moving average is $14.56 and its 200 day simple moving average is $15.84.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.11). Immunome had a negative return on equity of 38.19% and a negative net margin of 2,435.02%. The business had revenue of $2.36 million for the quarter, compared to analyst estimates of $2.62 million. Equities research analysts expect that Immunome, Inc. will post -1.92 EPS for the current year.

Insider Buying and Selling

In other news, insider Jack Higgins sold 3,524 shares of the stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $13.93, for a total value of $49,089.32. Following the completion of the sale, the insider now owns 16,000 shares of the company’s stock, valued at $222,880. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, insider Jack Higgins sold 3,524 shares of Immunome stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $13.93, for a total value of $49,089.32. Following the transaction, the insider now directly owns 16,000 shares of the company’s stock, valued at $222,880. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Jean Jacques Bienaime bought 7,000 shares of the firm’s stock in a transaction on Friday, August 16th. The shares were purchased at an average cost of $13.94 per share, with a total value of $97,580.00. Following the transaction, the director now directly owns 16,615 shares in the company, valued at approximately $231,613.10. The disclosure for this purchase can be found here. 8.60% of the stock is owned by corporate insiders.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.